Cytoreductive surgery in ovarian cancer

Cancer Imaging

Volumn 7, Issue 1, 2007, Pages 210-215

  Pomel, Christophe ^a,b   Jeyarajah, Arjun ^a   Oram, David ^a   Shepherd, John ^a   Milliken, David ^a   Dauplat, Jacques ^b   Reynolds, Karina ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b Jean Perrin Comprehensive Cancer Centre   (France)

Author keywords

Cytoreductive surgery; Ovarian cancer

Indexed keywords

CANCER STAGING; CARCINOMA; DIAGNOSTIC IMAGING; FEMALE; HUMAN; LYMPHADENECTOMY; METASTASIS; OVARY TUMOR; PATHOLOGY; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; SURVIVAL RATE;

CARCINOMA; DIAGNOSTIC IMAGING; FEMALE; HUMANS; LYMPH NODE EXCISION; NEOPLASM METASTASIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SURVIVAL RATE;

EID: 38449115940     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2007.0030     Document Type: Article

References (30)

1. Young RC, Walton LA, Elleberg SS, et al. Adjuvant therapy in stage 1 and stage Il epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990; 322: 1021-7. (Pubitemid 20146659)
2. Berek JS. Epithelial ovarian cancer. Practical gynecologic oncology. Baltimore, MD: Williams and Wilkins; 1988, p. 327-64.
3. Averette HE, Hoskins W, Nguyen HN, et al. National survey of ovarian carcinoma. A patient care evaluation study of the American College of Surgeons. Cancer 1993; 71: suppl 4): 1629-38.
4. Mayer AR, Chambers SK, Graves E, et al. Ovarian cancer staging: does it require a gynecologic oncologist ? Gynecol Oncol 1992; 47: 223-7. (Pubitemid 23001332)
5. Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 2003; 95: 113-25. (Pubitemid 36193260)
6. Leblanc E, Querleu D, Narducci F, et al. Surgical staging of early invasive epithelial ovarian tumors. Semin Surg Oncol 2000; 19: 36-41. (Pubitemid 30439313)
7. Morice P, Joulie F, Camatte S, et al Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg 2003; 197: 198-205.
8. Di Re F, Baiocchi G. Value of lymph node assessment in ovarian cancer: status of the art at the end of the second millennium. Int J Gynecol Cancer 2000; 10: 435-42
9. Fontanelli R, Paladini D, Raspagliesi F, Di Re E. The role of appendicectomy in surgical procedure for ovarian cancer. Gynecol Oncol 1992; 46: 42-4.
10. Maggioni A, Benedetti Panici P, Dell'Anna T, et al Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 2006; 95: 699-704. (Pubitemid 44373484)
11. Hudson CN. Surgical treatment of ovarian cancer. Gynecol Oncol 1973; 1: 370-8.
12. Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 2003; 90: 390-6. (Pubitemid 36952033)
13. Aletti GD, Long HJ, Podratz KC, Cliby WA. Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer? Gynecol Oncol 2007; 104: 212-6. (Pubitemid 46070191)
14. Gadducci A, Sartori E, Landoni F, et al Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study. J Clin Oncol 2005; 23: 751-8. (Pubitemid 46224174)
15. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a metaanalysis. J Clin Oncol 2002; 20: 1248-59. (Pubitemid 34177431)
16. Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol 2005; 23: 8802-11. (Pubitemid 46211526)
17. Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A, for the AGO-OVAR.Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 2007; 106: 69-74. (Pubitemid 46898573)
18. Chi DS, Franklin CC, Levine DA, et al Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 2004; 94: 650-4. (Pubitemid 39194456)
19. Benedetti Panici P, Maggioni A, Hacker N, et al Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005; 97: 560-6. (Pubitemid 40723783)
20. Chan JK, Urban R, Hu JM, et al The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients. Br J Cancer 2007; 96: 1817-22. (Pubitemid 46912018)
21. van der Burg MEL, van Lent M, Buyse M, et al The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995; 332: 629-34.
22. McGuire WP, Hoskins WJ, Brady MF, et al Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6. (Pubitemid 26012496)
23. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 2007; 106: 274-5. (Pubitemid 46898584)
24. Bristow RE, Berek JS. Surgery for ovarian cancer: how to improve survival. Lancet 2006; 367: 1558-60. (Pubitemid 43674219)
25. Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993; 11: 166-72. (Pubitemid 23059991)
26. Axtell AE, Lee MH, Bristow RE, et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol 2007; 25: 384-9. (Pubitemid 350002986)
27. Deffieux X, Castaigne D, Pomel C. Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. Int J Gynecol Cancer 2006; 16 ( Suppl 1): 35-40.
28. Fagotti A, Fanfani F, Ludovisi M, et al Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecol Oncol 2005; 96: 729-35. (Pubitemid 40255493)
29. Harmon RL, Sugarbaker P. Prognostoc indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2005; 2: 3.
30. Pomel C, Dauplat J. Management of malignant epithelial tumors of the ovary. J Chir (Paris) 2004; 141: 277-84. (Pubitemid 39420749)